Harrow Inc is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of innovative ophthalmic solutions
The company aims to improve patient outcomes through its portfolio of prescription eye medications, which are designed to address various ocular conditions and diseases. Harrow combines its expertise in drug formulation and compounding with a commitment to enhancing the quality of life for patients suffering from eye-related issues, positioning itself as a leader within the ophthalmic pharmaceutical sector. Through strategic partnerships and a dedication to research and development, Harrow strives to expand its offerings and address unmet medical needs in the eye care market.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSECOR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their staff, and patients. Through a state-of-the-art patient support services hub, Harrow Cares ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize IHEEZO® and TRIESENCE® in their practices.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSRX, Inc. and its related party, Ocular Science, Inc. An eight-person jury in the United States District Court for the Southern District of California unanimously validated the entirety of ImprimisRx’s subject trademark estate and found OSRX, Inc. or Ocular Science, Inc. acted with malice, fraud, or oppression, willfully engaging in trademark infringement and unfair competition under California and federal law. The $34.9 million verdict includes $20.4 million in punitive damages and $14.5 million in actual damages.
Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration (“FDA”) earlier this year, this study design and these positive results support the necessary objectives required for a regulatory submission.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This initiative reflects Harrow’s ongoing commitment to making essential, sight-saving medications accessible and affordable.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow’s ophthalmic branded products, including FLAREX®, ILEVRO®, MAXIDEX®, MAXITROL®, NATACYN®, NEVANAC®, TOBRADEX® ST, VERKAZIA®, VEVYE®, VIGAMOX®, and ZERVIATE®, by simplifying the prescribing process for eyecare professionals and improving both accessibility and affordability for patients.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update.
Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the last patient in its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville.
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York:
